Chargement en cours...
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
OBJECTIVE: Tofacitinib is an oral JAK inhibitor that is used for the treatment of rheumatoid arthritis (RA). In previous clinical trials of tofacitinib, a Disease Activity Score in 28 joints (DAS28)–based analysis was used to assess outcomes. In this study, remission rates according to various remis...
Enregistré dans:
| Publié dans: | Arthritis Rheumatol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5396306/ https://ncbi.nlm.nih.gov/pubmed/27907269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39996 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|